# Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

> **NCT06580314** · PHASE3 · RECRUITING · sponsor: **NRG Oncology** · enrollment: 880 (estimated)

## Conditions studied

- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube High Grade Serous Adenocarcinoma
- FIGO Stage III Ovarian Cancer 2014
- FIGO Stage IV Ovarian Cancer 2014
- Ovarian Carcinoma
- Ovarian High Grade Endometrioid Adenocarcinoma
- Ovarian High Grade Serous Adenocarcinoma
- Primary Peritoneal Endometrioid Adenocarcinoma
- Primary Peritoneal High Grade Serous Adenocarcinoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT06580314
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-12
- **Primary completion:** 2034-12-31
- **Final completion:** 2034-12-31
- **Target enrollment:** 880 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06580314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06580314, "Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06580314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*